Skip to main content
main-content

Insulin

23-09-2022 | EASD 2022 | Conference coverage | News

Bolus timing requires more attention in people using advanced technologies for type 1 diabetes

Delayed prandial insulin boluses are common in people using advanced technologies for the management of type 1 diabetes and are associated with adverse glycemic outcomes, suggest real-world study results.

22-09-2022 | EASD 2022 | Conference coverage | News

Model could predict severe hypoglycemia risk in people with type 2 diabetes

A number of factors are associated with severe hypoglycemia risk in people with type 2 diabetes treated with insulin or sulfonylureas, suggests research reported at the 58th EASD Annual Meeting in Stockholm, Sweden.

20-09-2022 | EASD 2022 | Conference coverage | News

Freestyle Libre cuts acute complication risk in insulin-treated type 2 diabetes

People taking basal insulin to treat type 2 diabetes experience a significant reduction in the risk for acute complications, which is sustained for at least 2 years after initiating use of the Freestyle Libre, say French researchers.

08-08-2022 | Insulin | News

Daily insulin dose may be linked to cancer risk in type 1 diabetes

People with type 1 diabetes who take a higher daily dose of insulin may have an increased risk for cancer compared with those on lower doses, US researchers report.

06-07-2022 | Artificial pancreas systems | News

Hybrid closed-loop system brings benefits even with lax bolusing

Use of the Tandem Control IQ hybrid closed-loop insulin delivery system improves time in range even for users who very rarely bolus for meals or to treat hyperglycemia, an observational study suggests.

15-06-2022 | Insulin | News

Liver-targeted insulin reduces hypoglycemic events

Switching 1% of standard bolus insulin lispro to a liver-targeted formulation decreases hypoglycemic events without affecting glucose control, OPTI-1 study findings indicate.

06-06-2022 | ADA 2022 | Conference coverage | News

​​​​​​​Hypoglycemia risk from insulin overdose no worse with icodec than glargine

The risk for hypoglycemia from an accidental basal insulin overdose is no higher with weekly insulin icodec than with daily glargine U100 in people with type 2 diabetes, report researchers.

05-06-2022 | ADA 2022 | Conference coverage | News

​​​​​​​Ultra-rapid lispro noninferior to standard version in children

Ultra-rapid lispro gives equivalent overall glycemic control to standard lispro, and is significantly better for some postprandial measurements in children with type 1 diabetes, shows the PRONTO-Peds trial.